GSK (FKA GLAXOSMITHKLINE INC.)

15 federal lobbying filings, 2023 to 2026.

GSK (FKA GLAXOSMITHKLINE INC.) is a client on 15 federal lobbying filings, 2023 to 2026. Based in District of Columbia.

An LDA filing reports one registrant’s income from one client for everything they worked that quarter, so a total here is the sum of whole filings and never a price for one issue or one bill.

Firms

1 it has hired, by filings.

Registrant	Filings	Reported
GSK (FKA GLAXOSMITHKLINE INC.)	15	—

By year

Filings and what they reported, newest year first.

Year	Filings	Income	Expenses
2026	2	—	$2.5M
2025	5	—	$5.6M
2024	4	—	$4.8M
2023	4	—	$5.1M

Issues

The LDA issue codes the filings were filed under.

Code	Issue	Filings
`BUD`	Budget/Appropriations	15
`CPT`	Copyright/Patent/Trademark	15
`HCR`	Health Issues	15
`MMM`	Medicare/Medicaid	15
`TRD`	Trade (domestic/foreign)	15

Bills

The bills the filings name, by how many name them.

Bill	Title	Filings
H.Con.Res. 14	Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…	7
H.R. 1492	To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…	7
H.R. 2214	DRUG Act	7
H.R. 946	ORPHAN Cures Act	7
S. 1040	Drug Competition Enhancement Act	7
S. 1041	Affordable Prescriptions for Patients Act	7
S. 1095	Stop STALLING Act	7
S. 1096	Preserve Access to Affordable Generics and Biosimilars Act	7
S. 43	Skinny Labels, Big Savings Act	7
S. 832	EPIC Act of 2025	7
S. 864	HELP Copays Act	7
S. 891	Bipartisan Health Care Act	7
H.R. 1574	RESTORE Patent Rights Act of 2025	6
H.R. 890	Stopping Pharma’s Ripoffs and Drug Savings For All Act	6
S. 1097	Interagency Patent Coordination and Improvement Act of 2025	6
S. 708	RESTORE Patent Rights Act of 2025	6
H.R. 1	An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.	5
H.R. 1262	Mikaela Naylon Give Kids a Chance Act	5
H.R. 3152	Patent Eligibility Restoration Act of 2025	5
H.R. 3160	PREVAIL Act	5
H.R. 3269	ETHIC Act	5
H.R. 4121	Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026	5
S. 1414	Expedited Access to Biosimilars Act	5
S. 1546	Patent Eligibility Restoration Act of 2025	5
S. 1553	PREVAIL Act	5

Lobbyists

Named on the filings.

Lobbyist	Clients	Filings
MONICA CLOUD	1	13
PHILIP THEVENET	1	13
LIAM MACDONALD	1	10
CURTIS RHYNE	1	9
HARMEET DHILLON	1	9
MICHAEL CALVO	1	9
AMY EFANTIS	1	6
ALEC HINOJOSA	1	4
BRENTON FISK	1	4
SHIRA KILCOYNE	1	4
CARA WALTHER	1	1
JASEY CARDENAS	1	1

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, newest first.

Lobbying Finance